1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
2Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Korea
3Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
5Department of Radiology, Seoul National University College of Medicine, Seoul, Korea
Copyright © 2015 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | No. of patients (%) |
---|---|
Age (yr) | 64 (38-80)a) |
Gender | |
Male | 31 (50.0) |
Female | 31 (50.0) |
Performance (ECOG) | |
0, 1 | 58 (93.5) |
2 | 4 (6.5) |
Splenic artery invasion | |
Yes | 36 (58.1) |
No | 26 (41.9) |
Splenic vein invasion | |
Yes | 43 (69.4) |
No | 19 (30.6) |
Pathologic T stage | |
T1-2 | 2 (3.2) |
T3 | 57 (91.9) |
T4 | 3 (4.8) |
Pathologic N stage | |
N0 | 29 (46.8) |
N1 | 33 (53.2) |
Resection margin involvement | |
Yes | 11 (17.7) |
No | 51 (82.3) |
Angiolymphatic invasion | |
Yes | 18 (29.0) |
No | 44 (71.0) |
Venous invasion | |
Yes | 16 (25.8) |
No | 46 (74.2) |
Perineural invasion | |
Yes | 48 (77.4) |
No | 12 (19.4) |
Unknown | 2 (3.2) |
Variable | No. of patients | Median DFS (mo) | p-valuea) | Median OS (mo) | p-valuea) |
---|---|---|---|---|---|
Age (yr) | 0.6466 | 0.4041 | |||
< 65 | 34 | 15.4 | 34.7 | ||
≥ 65 | 28 | 15.0 | 50.0 | ||
Gender | 0.1063 | 0.0432 | |||
Male | 31 | 10.5 | 23.8 | ||
Female | 31 | 22.5 | 61.3 | ||
Performance (ECOG) | 0.2269 | 0.3790 | |||
0-1 | 58 | 15.9 | 37.5 | ||
2 | 4 | 7.6 | 10.8 | ||
SA invasion | 0.0123 | 0.1084 | |||
Yes | 36 | 11.0 | 27.6 | ||
No | 26 | 49.2 | 68.6 | ||
SV invasion | 0.1723 | 0.5081 | |||
Yes | 43 | 15.4 | 37.5 | ||
No | 19 | 49.2 | 68.6 | ||
Tumor size (cm) | 0.2070 | 0.6161 | |||
< 3 | 27 | 17.3 | 37.5 | ||
≥ 3 | 35 | 12.4 | 45.8 | ||
RM involvement | 0.0002 | 0.0002 | |||
Yes | 11 | 8.2 | 16.3 | ||
No | 51 | 18.4 | 50.0 | ||
Lymph node metastasis | 0.1115 | 0.1994 | |||
Yes | 33 | 10.4 | 34.7 | ||
No | 29 | 27.6 | 50.0 | ||
Angiolymphatic invasion | 0.0503 | 0.0138 | |||
Yes | 18 | 8.2 | 13.8 | ||
No | 44 | 18.2 | 61.3 | ||
Venous invasion | 0.0008 | 0.0206 | |||
Yes | 16 | 10.4 | 18.5 | ||
No | 46 | 22.5 | 54.7 | ||
Perineural invasion | 0.0912 | 0.4778 | |||
Yes | 48 | 12.1 | 34.7 | ||
No | 12 | NR | 54.7 | ||
RT dose (Gy) | 0.3948 | 0.1978 | |||
< 50 | 13 | 10.4 | 22.0 | ||
≥ 50 | 49 | 17.3 | 54.7 | ||
Op-RT duration (day) | 0.7631 | 0.9182 | |||
< 45 | 32 | 18.4 | 37.5 | ||
≥ 45 | 30 | 11.0 | 50.0 | ||
Concurrent chemotherapy | 0.8668 | 0.8968 | |||
Gemcitabine | 16 | 10.1 | 17.9 | ||
Others | 46 | 16.5 | 37.5 |
Variable |
Disease-free survival |
Overall survival |
||||
---|---|---|---|---|---|---|
HR | 95% CI | p-valuea) | HR | 95% CI | p-valuea) | |
Male, gender | 2.137 | 1.065-4.286 | 0.0325 | |||
SA invasion | 2.193 | 1.140-4.219 | 0.0186 | 1.473 | 0.706-3.071 | 0.3017 |
RM involvement | 3.706 | 1.791-7.669 | 0.0004 | 4.157 | 1.829-9.445 | 0.0007 |
Lymph node metastasis | 1.431 | 0.774-2.645 | 0.2534 | 1.535 | 0.770-3.063 | 0.2238 |
Characteristic | No. of patients (%) |
---|---|
Age (yr) | 64 (38-80) |
Gender | |
Male | 31 (50.0) |
Female | 31 (50.0) |
Performance (ECOG) | |
0, 1 | 58 (93.5) |
2 | 4 (6.5) |
Splenic artery invasion | |
Yes | 36 (58.1) |
No | 26 (41.9) |
Splenic vein invasion | |
Yes | 43 (69.4) |
No | 19 (30.6) |
Pathologic T stage | |
T1-2 | 2 (3.2) |
T3 | 57 (91.9) |
T4 | 3 (4.8) |
Pathologic N stage | |
N0 | 29 (46.8) |
N1 | 33 (53.2) |
Resection margin involvement | |
Yes | 11 (17.7) |
No | 51 (82.3) |
Angiolymphatic invasion | |
Yes | 18 (29.0) |
No | 44 (71.0) |
Venous invasion | |
Yes | 16 (25.8) |
No | 46 (74.2) |
Perineural invasion | |
Yes | 48 (77.4) |
No | 12 (19.4) |
Unknown | 2 (3.2) |
Variable | No. of patients | Median DFS (mo) | p-value |
Median OS (mo) | p-value |
---|---|---|---|---|---|
Age (yr) | 0.6466 | 0.4041 | |||
< 65 | 34 | 15.4 | 34.7 | ||
≥ 65 | 28 | 15.0 | 50.0 | ||
Gender | 0.1063 | 0.0432 | |||
Male | 31 | 10.5 | 23.8 | ||
Female | 31 | 22.5 | 61.3 | ||
Performance (ECOG) | 0.2269 | 0.3790 | |||
0-1 | 58 | 15.9 | 37.5 | ||
2 | 4 | 7.6 | 10.8 | ||
SA invasion | 0.0123 | 0.1084 | |||
Yes | 36 | 11.0 | 27.6 | ||
No | 26 | 49.2 | 68.6 | ||
SV invasion | 0.1723 | 0.5081 | |||
Yes | 43 | 15.4 | 37.5 | ||
No | 19 | 49.2 | 68.6 | ||
Tumor size (cm) | 0.2070 | 0.6161 | |||
< 3 | 27 | 17.3 | 37.5 | ||
≥ 3 | 35 | 12.4 | 45.8 | ||
RM involvement | 0.0002 | 0.0002 | |||
Yes | 11 | 8.2 | 16.3 | ||
No | 51 | 18.4 | 50.0 | ||
Lymph node metastasis | 0.1115 | 0.1994 | |||
Yes | 33 | 10.4 | 34.7 | ||
No | 29 | 27.6 | 50.0 | ||
Angiolymphatic invasion | 0.0503 | 0.0138 | |||
Yes | 18 | 8.2 | 13.8 | ||
No | 44 | 18.2 | 61.3 | ||
Venous invasion | 0.0008 | 0.0206 | |||
Yes | 16 | 10.4 | 18.5 | ||
No | 46 | 22.5 | 54.7 | ||
Perineural invasion | 0.0912 | 0.4778 | |||
Yes | 48 | 12.1 | 34.7 | ||
No | 12 | NR | 54.7 | ||
RT dose (Gy) | 0.3948 | 0.1978 | |||
< 50 | 13 | 10.4 | 22.0 | ||
≥ 50 | 49 | 17.3 | 54.7 | ||
Op-RT duration (day) | 0.7631 | 0.9182 | |||
< 45 | 32 | 18.4 | 37.5 | ||
≥ 45 | 30 | 11.0 | 50.0 | ||
Concurrent chemotherapy | 0.8668 | 0.8968 | |||
Gemcitabine | 16 | 10.1 | 17.9 | ||
Others | 46 | 16.5 | 37.5 |
Variable | Disease-free survival |
Overall survival |
||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value |
HR | 95% CI | p-value |
|
Male, gender | 2.137 | 1.065-4.286 | 0.0325 | |||
SA invasion | 2.193 | 1.140-4.219 | 0.0186 | 1.473 | 0.706-3.071 | 0.3017 |
RM involvement | 3.706 | 1.791-7.669 | 0.0004 | 4.157 | 1.829-9.445 | 0.0007 |
Lymph node metastasis | 1.431 | 0.774-2.645 | 0.2534 | 1.535 | 0.770-3.063 | 0.2238 |
Values are presented as median (range). ECOG, Eastern Cooperative Oncology Group.
DFS, disease-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; SA, splenic artery; SV, splenic vein; RM, resection margin; NR, not reached; RT, radiotherapy; Op, operation. Log-rank test.
HR, hazard radio; CI, confidence interval; SA, splenic artery; RM, resection margin. Cox proportional hazard model.